Compare BCTX & IINN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BCTX | IINN |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | Canada | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.5M | 35.3M |
| IPO Year | N/A | 2021 |
| Metric | BCTX | IINN |
|---|---|---|
| Price | $9.90 | $1.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $40.00 | $2.00 |
| AVG Volume (30 Days) | 55.2K | ★ 119.2K |
| Earning Date | 12-11-2025 | 10-01-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $289,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $380.95 | $2,582.74 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.00 | $0.40 |
| 52 Week High | $106.50 | $1.65 |
| Indicator | BCTX | IINN |
|---|---|---|
| Relative Strength Index (RSI) | 44.95 | 59.72 |
| Support Level | $11.38 | $1.03 |
| Resistance Level | $13.09 | $1.18 |
| Average True Range (ATR) | 1.14 | 0.06 |
| MACD | 0.06 | 0.01 |
| Stochastic Oscillator | 30.12 | 84.94 |
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.
Inspira Technologies Oxy BHN Ltd is a specialty medical device company engaged in the research, development, manufacture, and marketing of proprietary respiratory support technology that is intended to provide an alternative to invasive mechanical ventilation (MV), which is the standard of care today for the treatment of respiratory failure. The respiratory care devices market is segmented geographically into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.